| Literature DB >> 34702986 |
Winnie Kavulani Luseno1, Stuart Rennie2,3, Adam Gilbertson4.
Abstract
Ideally, the benefits of public health interventions should outweigh any associated harms, burdens, and adverse unintended consequences. The intended benefit of voluntary medical male circumcision (VMMC) programs in eastern and southern Africa (ESA) is the reduction of HIV infections. We review the literature for evidence of reductions in HIV incidence, evaluate the extent to which decreases in HIV incidence can be reasonably attributed to VMMC programs, and summarize social harms and ethical concerns associated with these programs. Review findings suggest that HIV incidence had been declining across ESA since before the large-scale rollout of VMMC as a public health intervention, and that this decline may be due to the combined effects of HIV prevention and treatment interventions, such as expanded antiretroviral therapy. The independent effect of VMMC programs in reducing HIV infections at the population level remains unknown. On the other hand, VMMC-associated evidence is increasing for the existence of negative social impacts such as stigmatization and/or discrimination, and ethically problematic practices, including lack of informed consent. We conclude that the relationship between the benefits and burdens of VMMC programs may be more unfavorable than what has been commonly suggested by proponents of global VMMC campaigns.Entities:
Year: 2021 PMID: 34702986 PMCID: PMC8545773 DOI: 10.1038/s41443-021-00484-x
Source DB: PubMed Journal: Int J Impot Res ISSN: 0955-9930 Impact factor: 2.408
Change in new HIV infections in the priority ESA countries.
| Country | Annualized rate of change in new infections (95% uncertainty interval)a | Change in new HIV infections since 2010b | |
| 1990–2007 | 2007–2017 | ||
| Botswana | −3.1% | −5.3% | −34% |
| (−4.5 to −1.8) | (−9.1 to −1.7) | ||
| eSwatini | 14.2% | −21.8% | −66% |
| (8.5–19.5) | (−36.1 to −15.1) | ||
| Ethiopia | −18.9% | −1.3% | −46% |
| (−21.5 to −16.3) | (−7.6 to 4.1) | ||
| Kenya | −6.1% | −3.5% | −44% |
| (−7.5 to −4.8) | (−6.3 to −0.5) | ||
| Lesotho | 2.8% | −7.1% | −45% |
| (1.1–4.5) | (−10.7 to −4.4) | ||
| Malawi | −7.0% | −10.8% | −41% |
| (−8.5 to −5.5) | (−18.9 to −5.3) | ||
| Mozambique | 5.4% | −5.2% | −17% |
| (3.5–7.5) | (−9.5 to −1.7) | ||
| Namibia | 2.4% | −5.8% | −36% |
| (0.8–5.1) | (−10.8 to −1.2) | ||
| Rwanda | −6.1% | −7.2% | −47% |
| (−9.3 to −2.1) | (−11.7 to −2.5) | ||
| South Africa | 12.8% | −5.7% | −53% |
| (11.3–14.2) | (−7.9 to −3.8) | ||
| South Sudan | 0.2% | −5.7% | 17% |
| (−5.4 to 9.5) | (−15.6 to −2.9) | ||
| Tanzania | −8.3% | −6.6% | −19% |
| (−10.8 to −6.0) | (−41.9 to 7.7) | ||
| Uganda | −3.8% | −11.4% | −43% |
| (−7.7 to 0.2) | (−35.9 to 2.5) | ||
| Zambia | −5.4% | −8.3% | −15% |
| (−6.7 to −4.2) | (−12.2 to −4.2) | ||
| Zimbabwe | −8.5% | −3.0% | −44% |
| (−11.0 to −6.3) | (−40.1 to 7.9) | ||
| Sub-Saharan Africa | −2.8% | −5.9% | |
| (−3.8 to −1.9) | (−8.2 to −3.6) | ||
| Global | −0.4% | −3.0% | |
| (−1.2 to 0.3) | (−4.5 to −1.5) | ||
Sources: aGBD 2017 and bUNAIDS 2020.
Yearly country performance of voluntary medical male circumcisions in 15 priority countries from eastern and southern Africa: 2008–2018.
| 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | Total 2016–2018 | Total 2008–2018 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botswana | - | 5,424 | 5,773 | 14,661 | 38,005 | 46,793 | 30,033 | 15,722 | 24,042 | 19,756 | 24,207 | 68,005 | 224,416 |
| Eswatini | 1,110 | 4,336 | 18,869 | 13,791 | 9,977 | 10,105 | 12,289 | 12,952 | 17,374 | 18,138 | 14,316 | 49,828 | 133,257 |
| Ethiopia* | - | 769 | 2,689 | 7,542 | 11,961 | 16,393 | 11,831 | 9,744 | 10,306 | 15,789 | 23,009 | 49,104 | 110,033 |
| Kenya | 11,663 | 80,719 | 139,905 | 159,196 | 151,517 | 190,580 | 193,576 | 207,014 | 219,086 | 233,879 | 286,899 | 739,864 | 1,874,034 |
| Lesotho | - | - | - | - | 10,835 | 37,655 | 36,245 | 25,966 | 34,157 | 25,150 | 26,448 | 85,755 | 196,456 |
| Malawi | 589 | 1,234 | 1,296 | 11,881 | 21,250 | 40,835 | 80,419 | 108,672 | 129,975 | 166,350 | 199,399 | 495,724 | 761,900 |
| Mozambique | - | 100 | 7,633 | 29,592 | 135,000 | 146,046 | 240,507 | 198,340 | 253,079 | 315,380 | 311,891 | 880,350 | 1,637,568 |
| Namibia | - | 224 | 1,763 | 6,123 | 4,863 | 1,182 | 4,165 | 17,388 | 27,340 | 30,134 | 34,942 | 92,416 | 128,124 |
| Rwanda | - | - | 1,694 | 25,000 | 138,711 | 116,029 | 173,191 | 138,216 | 137,218 | 264,973 | 327,904 | 730,095 | 1,322,936 |
| South Africa | 5,190 | 9,168 | 131,117 | 296,726 | 422,009 | 514,991 | 482,474 | 485,552 | 497,186 | 511,191 | 572,442 | 1,580,819 | 3,928,046 |
| South Sudan** | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1,147 | 1,147 | 1,147 |
| Uganda | - | - | 21,072 | 77,756 | 368,490 | 801,678 | 878,109 | 556,546 | 411,459 | 847,633 | 619,082 | 1,878,174 | 4,581,825 |
| United Republic of Tanzania | - | 1,033 | 18,026 | 120,261 | 183,480 | 329,729 | 573,845 | 435,302 | 548,390 | 730,435 | 885,599 | 2,164,424 | 3,826,100 |
| Zambia | 2,758 | 17,180 | 61,911 | 85,151 | 173,992 | 294,466 | 315,168 | 222,481 | 311,792 | 483,816 | 482,183 | 1,277,791 | 2,450,898 |
| Zimbabwe | - | 2,801 | 11,176 | 36,603 | 40,755 | 112,084 | 209,125 | 188,732 | 205,784 | 301,366 | 326,012 | 833,162 | 1,434,438 |
Source: 2019 Global AIDS Monitoring.
*In Ethiopia, implementation of VMMC is in the Gambela region.
**South Sudan has only recently initiated a pilot VMMC program, and its data were reported for the first time in 2018.
Summary of findings from studies examining the effectiveness of VMMC and ART in reducing HIV incidence.
| First author (year)/study purpose | Country/study period | Research design/sample | Results |
|---|---|---|---|
Kagaayi et al. (2019) [ To assess the impact of combination HIV interventions on HIV incidence in four HIV-hyperendemic communities. | Uganda 2011–2017 | Open population-based prospective cohort study Males and females aged 15−49 years | ↑ ART use from 16% at baseline to 82% at final survey. ↑ Population viral load suppression among HIV+ from 34% at baseline to 80% at final survey. ↑ Male circumcision coverage from 35% at baseline to 65% at final survey. ↓ HIV prevalence from 41% at baseline to 37% at final survey. ↓ HIV incidence from 3.43 per 100 person-years (95% CI, 2.45–4.67) at baseline to 1.59 per 100 person-years (95% CI, 1.19–2.07) at final survey. Male circumcision associated with decreased HIV incidence. |
Loevinsohn et al. (2020) [ To assess the impact of a PEPFAR-supported VMMC program on the risk of male HIV acquisition over time. | Uganda 2008–2016 | Open population-based prospective cohort study Analytical sample restricted to non-Muslim HIV uninfected and uncircumcised men at study entry Five survey rounds denoted as 13–17 | 34% of eligible men were circumcised between 2008 and 2016. ↓ HIV incidence in circumcised men (0.86 infections per 100 person-years for survey rounds 13–14 vs 0.30 infections per 100 person-years for survey rounds 15–17; men who were non-circumcised (1.33 infections per 100 person-years for survey rounds 13–14 vs 0.74 infections per 100 person-years for survey rounds 15–17. VMMC associated with 51% lower risk of incident HIV infection. |
Makhema et al. (2019) [ To determine whether and to what degree a community-based intervention to maximize HIV testing and case identification, linkage to care, early (expanded) ART, and male circumcision could reduce the population-level incidence of HIV infection. | Botswana 2013–2018 | Pair-matched community-randomized trial Residents from random sample of ~20% of households in each community. | ↓ HIV incidence ratio in intervention group compared with standard-care group. ↑ (Nonsignificant) effect of intervention than standard care on incidence of HIV infection among men. ↑ Increase in percentage of virally suppressed HIV-positive participants in intervention communities (from 70 to 88%) than in standard-care communities (from 75 to 83%) (relative risk, 1.12; 95% CI, 1.09–1.16). Among HIV+ not receiving ART at enrollment, median time to initiation of ART was 69 days in the intervention group compared to 367 days in the standard-care group. ↑ in % of HIV− men aged 16–49 years who reported being circumcised from 30% at baseline to 40% at trial end in the intervention group, as compared with an increase from 33 to 35% in the standard-care group (relative risk, 1.26; 95% CI, 1.17–1.35). |
Vandormael et al. (2019) [ To quantify sex-specific trends in HIV incidence following changes in ART coverage, prevalence of detectable viremia, condom use, and male circumcision. | South Africa 2005–2017 | Prospective cohort of repeat HIV testers in a population-based HIV testing platform | ↓ HIV incidence rates (IRs) when opposite-sex ART coverage surpassed 35% and ART eligibility criteria were removed in 2016. ↓ HIV incidence between 2012 and 2017 among men from 2.49 (95% CI, 1.83–3.37) to 1.01 (95% CI, 0.58–1.76) seroconversion events per 100 person-years. ↓ HIV incidence between 2014 and 2017 among females from 4.89 (95% CI, 4.09, 5.84) to 3.06 (95% CI, 2.38–3.94) seroconversion events per 100 person-years. ↑ ART coverage among HIV + women from 2.1% in 2005 to 54.6% in 2017 and among HIV+ men from 1.5% in 2005 to 38.4% in 2017. ↓ Population prevalence of detectable viremia among women from 72.8% in 2011 to 55.3% in 2014 and among men from 77.8% in 2011 to 67.2% in 2014. ↑ Self-reported circumcision among men from 3.0 to 32.9% between 2009–2016. ↓ HIV IR between 2012 and 2016 from 1.24 (95% CI, 0.57–2.69) to 0.5 (95% CI, 0.16–1.57) events per100 person-years among circumcised men and from 3.01 (95% CI, 2.16–4.18) to 1.73 (95% CI, 1.01–2.97) events per100 person-years among uncircumcised men. ↓ Adjusted incidence rate ratio among circumcised men compared with uncircumcised men and among circumcised and uncircumcised men compared with women. |
Borgdorff et al. (2018) [ To determine the trends in HIV prevalence and incidence. | Kenya 2011−2016 | Secondary analysis of data from a health and demographic surveillance system (HDSS) in which home-based counseling and testing (BCT) surveys have been done since 2011, to increase coverage of HIV control interventions. Age 13 and older | ↓ HIV incidence from 11.1 (95% CI, 9.1–13.1) per 1000 p-ys in 2011–12 to 5.7% (95% CI, 4.6–6.9) per 1000 p-ys in 2012–16. ↓ Adjusted HIV incidence ratio (0.5, 95% CI, 0.2–1.0) among females with a circumcised male partner than with uncircumcised male partner. ↓ (Non-significant) unadjusted HIV incidence ratio (0.7, 95% CI, 0.4–1.1) among circumcised males compared to uncircumcised males. |